Brokerages Anticipate CinCor Pharma, Inc. (NASDAQ:CINC) Will Post Earnings of -$0.50 Per Share

Wall Street analysts predict that CinCor Pharma, Inc. (NASDAQ:CINCGet Rating) will post ($0.50) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for CinCor Pharma’s earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.43). The business is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that CinCor Pharma will report full-year earnings of ($2.28) per share for the current year, with EPS estimates ranging from ($2.52) to ($1.95). For the next financial year, analysts expect that the business will post earnings of ($2.97) per share, with EPS estimates ranging from ($3.44) to ($2.66). Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for CinCor Pharma.

CinCor Pharma (NASDAQ:CINCGet Rating) last issued its earnings results on Tuesday, May 10th. The company reported ($0.50) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.50).

Several research analysts have issued reports on CINC shares. Jefferies Financial Group started coverage on shares of CinCor Pharma in a report on Tuesday, February 1st. They set a “buy” rating and a $30.00 target price on the stock. Evercore ISI started coverage on shares of CinCor Pharma in a report on Tuesday, February 1st. They set an “outperform” rating on the stock. Morgan Stanley initiated coverage on shares of CinCor Pharma in a report on Tuesday, February 1st. They set an “overweight” rating and a $27.00 target price on the stock. Finally, Oppenheimer initiated coverage on shares of CinCor Pharma in a report on Tuesday, February 1st. They issued an “outperform” rating and a $30.00 price target on the stock.

CINC stock traded up $1.19 during trading on Friday, hitting $16.54. The company had a trading volume of 55,752 shares, compared to its average volume of 184,256. CinCor Pharma has a 52-week low of $13.00 and a 52-week high of $30.66. The firm has a 50 day moving average of $20.01.

A number of institutional investors and hedge funds have recently bought and sold shares of CINC. UBS Group AG purchased a new position in CinCor Pharma during the 1st quarter worth approximately $38,000. California State Teachers Retirement System purchased a new position in shares of CinCor Pharma during the 1st quarter valued at approximately $87,000. JPMorgan Chase & Co. purchased a new position in shares of CinCor Pharma during the 1st quarter valued at approximately $95,000. American International Group Inc. purchased a new position in shares of CinCor Pharma during the 1st quarter valued at approximately $101,000. Finally, MetLife Investment Management LLC purchased a new position in shares of CinCor Pharma during the 1st quarter valued at approximately $142,000. 52.53% of the stock is owned by institutional investors.

About CinCor Pharma (Get Rating)

CinCor Pharma, Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases.

Read More

Get a free copy of the Zacks research report on CinCor Pharma (CINC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CinCor Pharma (NASDAQ:CINC)

Receive News & Ratings for CinCor Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CinCor Pharma and related companies with MarketBeat.com's FREE daily email newsletter.